Q-omics provides the consensus-scored STX1A profile across patient tissues and cancer cell-line models. STX1A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, STX1A is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, STX1A protein abundance shows 24,382 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where STX1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STX1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STX1A survival associations across molecular data types. STX1A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STX1A RNA expression–survival associations across cancer types. High STX1A expression shows unfavorable associations in KIRC, MESO, KIRP, LUSC, LIHC and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for STX1A RNA expression.
This table summarizes STX1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for STX1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STX1A shows higher tumor expression in HNSC, COAD, KIRP, LUAD, BLCA and LIHC. The HNSC box plot shows higher STX1A RNA expression in tumor versus normal tissue (log2 FC = +1.895, t-test p < 0.001).
This table shows molecular features associated with STX1A in patient tissues and cancer cell lines. In patient samples, STX1A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, STX1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SKIN.
